A Phase I Safety, Pharmacological, and Biological Study of the Farnesyl Protein Transferase Inhibitor, Lonafarnib (SCH 663366), in Combination With Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-007-0646-x
Full Text
Open PDFAbstract
Available in full text
Date
December 6, 2007
Authors
Publisher
Springer Science and Business Media LLC